XXI. ANNUAL MEETING German Society for Gene Therapy
Texcell Team at the XXI annual meeting German Society for Gene Therapy. Read More
Texcell Team at the XXI annual meeting German Society for Gene Therapy. Read More
THE CHALLENGE The efficiency of your vaccine candidate needs to be assessed in term of immunogenicity. Your drug may involuntarily impact the immune system (induction of drug/carrier specific T-cell response or specific antibodies). In order to address these 2 kind of issues,... Read More
THE CHALLENGES Contract research organisations (CRO) are an integral part of drug development. > 40% of Drug and Discovery process pass by CRO projects. More and more early development steps are devolved to CRO But how to choose the best... Read More
Texcell will be attending BioPharmaceutical Development and Production Week this upcoming March/April. Read More
Texcell will be attending the 5th Annual ISBiotech Spring Meeting located in Washington D.C. this coming Spring. The areas that will be discussed during this meeting will include products such as vaccines for numerous strains of flu and other potential... Read More